Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Viridian Therapeutics Inc | VRDN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 13.03 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.03 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 10.925 - 29.559 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 13.03 | USD |
Viridian Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 817.86M | 62.77M | - | 314k | -237.73M | -3.79 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Viridian Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRDN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.07 | 15.75 | 12.99 | 14.29 | 838,483 | -2.04 | -13.54% |
| 1 Month | 17.67 | 17.93 | 12.99 | 15.72 | 759,862 | -4.64 | -26.26% |
| 3 Months | 19.45 | 21.46 | 12.99 | 17.69 | 908,917 | -6.42 | -33.01% |
| 6 Months | 11.01 | 24.18 | 10.925 | 18.08 | 925,398 | 2.02 | 18.35% |
| 1 Year | 29.09 | 29.559 | 10.925 | 19.14 | 818,477 | -16.06 | -55.21% |
| 3 Years | 17.80 | 39.00 | 9.47 | 20.64 | 505,108 | -4.77 | -26.80% |
| 5 Years | 21.39 | 39.00 | 9.47 | 20.62 | 466,471 | -8.36 | -39.08% |
Viridian Therapeutics Description
| Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |
